Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Common side effects observed in monotherapy trials, similar to other GLP-1 receptor agonists, include gastrointestinal symptoms such as nausea, diarrhea, and vomiting, with most adverse events being mild to moderate in severity
The warning exists because: No safety data exists for GLP-1 agonist combinations in humans Overlapping receptor activation increases hypoglycemia risk, particularly with concurrent insulin use Gastrointestinal adverse events could compound to dangerous severity (dehydration from persistent vomiting) Drug-drug interaction studies for GLP-1 agonist combinations have not been conducted While retatrutide itself is not yet FDA-approved, the same pharmacological principle applies
10.1038/cddis.2017.21 107 WirthensohnG.GuderW
& Negishi, M
US$ 21.54
US$ 24.58
US$ 26.16
US$ 20.30
US$ 23.23
US$ 28.10
US$ 27.98
